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The global plan to eradicate hepatitis C virus (HCV) led by the World Health Organization outlines the use of 
highly effective direct-acting antiviral drugs (DAAs) to achieve elimination by 2030. Identifying individuals with 
active disease and investigation of the breadth of diversity of the virus in sub-Saharan Africa (SSA) is essential as 
genotypes in this region (where very few clinical trials have been carried out) are distinct from those found in other 
parts of the world. We undertook a population-based, nested case-control study in Uganda and obtained additional 
samples from the Democratic Republic of Congo (DRC) to estimate the prevalence of HCV, assess strategies for 
disease detection using serological and molecular techniques, and characterize genetic diversity of the virus. Using 
next-generation and Sanger sequencing, we aimed to identify strains circulating in East and Central Africa. A total 
of 7,751 Ugandan patients were initially screened for HCV, and 20 PCR-positive samples were obtained for sequenc-
ing. Serological assays were found to vary significantly in specificity for HCV. HCV strains detected in Uganda 
included genotype (g) 4k, g4p, g4q, and g4s and a newly identified unassigned g7 HCV strain. Two additional 
unassigned g7 strains were identified in patients originating from DRC (one partial and one full open reading frame 
sequence). These g4 and g7 strains contain nonstructural (ns) protein 3 and 5A polymorphisms associated with re-
sistance to DAAs in other genotypes. Clinical studies are therefore indicated to investigate treatment response in 
infected patients. Conclusion: Although HCV prevalence and genotypes have been well characterized in patients in 
well-resourced countries, clinical trials are urgently required in SSA, where highly diverse g4 and g7 strains circu-
late. (Hepatology 2019;69:1426-1441).
Hepatitis C virus (HCV) prevalence, geno-types, risk factors, and transmission patterns have only been partially characterized in sub-Saharan Africa (SSA) but are necessary to inform public health policy for preventive and therapeutic strategies in this region. This is particularly pressing 
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in the context of the World Health Organization 
(WHO) HCV elimination plan, scheduled for 2030. 
WHO guidelines recommend the use of direct- 
acting antiviral drugs (DAAs) as the first-line therapy 
for all.(1) Although DAAs are cheap to manufacture 
and generic formulations are being rapidly developed, 
several barriers may hinder efforts to eradicate the 
virus. Importantly, only 20% of those infected have 
been diagnosed,(2) and of those with known infection, 
some may be infected with strains that confer resis-
tance to DAAs. A lack of knowledge about strains 
circulating in SSA could affect treatment outcome.(3) 
Although far away from clinical use, the main vaccine 
candidate in clinical trials is based on genotype (g) 1b 
HCV.(4)
HCV is a member of the diverse Hepacivirus genus 
that includes viruses that infect humans, rodents, bats, 
canines, and horses.(5) To date, seven genotypes of 
HCV have been identified through phylogenetic anal-
ysis, which are further subdivided into 84 subtypes, 
many of which were identified in high-income coun-
tries (HICs).(6) Additionally, four sequences recently 
identified in India appear to fulfill the criteria for 
g8.(7) The open reading frames (ORFs) of HCV gen-
otypes differ from each other by at least 30% at the 
nucleotide level, whereas those of subtypes differ by 
10%-25%.(6) The genome consists of single-stranded 
positive-sense RNA with 5′ and 3′ untranslated regions 
(UTRs) and 10 genes that encode structural proteins 
and nonstructural proteins (NSs) (core, envelope E1 
and E2, p7, NS2, NS3, NS4A, NS4B, NS5A, and 
NS5B). Clinical features of infection with different 
genotypes are similar, with the consequent risk of 
cirrhosis and hepatocellular carcinoma, but response 
to treatment varies by genotype.(8) Encouragingly, 
pangenotypic combinations of antiviral drugs have 
recently been licensed; these have wide-ranging activ-
ity against the HCV subtypes present in HICs but 
have been less well assessed in the context of strains 
present in low-income and middle-income countries, 
particularly in SSA.(9)
The distribution of HCV genotypes varies sub-
stantially around the world.(3) g1a, g1b, and g3a 
have a global distribution, whereas subtypes of g3 
and g6 are found predominantly in Southern and 
South East Asia. g4 HCV is associated with infec-
tion in East, Central, and North Africa, where 
up to 20% of some older populations are infected 
with the virus through historical iatrogenic trans-
mission.(10,11) Few clinical trials have been carried 
out in SSA, where g1, g2, g4, g5, and g7 are pres-
ent, and very few sequences spanning the NS3, 
NS5A, and NS5B genes are available for analysis 
of potential resistance mutations.(12) Many of these 
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genotypes were sequenced in emigrants from Africa 
who were diagnosed with HCV in other countries, 
and it is therefore likely that these represent only a 
small sample of viral strains from a far larger pool 
of genetic diversity.(13-16) Accurate classification is 
clinically important because treatment response 
rates and treatment recommendations vary by geno-
type.(17) Understanding the extent of HCV genetic 
diversity would also aid the development of a vac-
cine to enhance elimination efforts and allow an 
increased understanding of recent and historical 
transmission patterns.
We therefore conducted a large-scale, popula-
tion-based study in Uganda to understand the burden 
of disease and identify strains circulating in this region. 
We sequenced samples from Uganda and Democratic 
Republic of Congo (DRC) that were both HCV anti-
body and RNA positive and samples that were RNA 
negative but seropositive using unbiased metagenomic 
sequencing and targeted PCR to investigate the diver-
sity of HCV in this region.
Participants and Methods
HUMaN paRtICIpaNtS
Patients were recruited in Uganda, DRC, and 
Canada. Informed consent in writing was obtained 
from the patients, and the study protocols conformed 
to the ethical guidelines of the 1975 Declaration of 
Helsinki as reflected in a priori approval by the appro-
priate institutional review committee.
UgaNDa
A cross-sectional, population-based survey of par-
ticipants aged 13 years and older within the Medical 
Research Council/Uganda Virus Research Institute 
(MRC/UVRI) General Population Cohort was car-
ried out in 2011,(18) and individuals were screened 
for HCV seropositivity. Of 8,056 cohort partici-
pants, Elecsys Anti-HCV II ImmunoAssay screening 
results were available for 7,751 (Fig. 1). To explore 
the accuracy of these screening results, all individ-
uals who were seropositive and a randomly selected 
sample of individuals who were HCV seronegative 
were invited to participate in a nested case-control 
study. Simultaneous baseline testing was carried out 
with two commercial assays: the US Food and Drug 
Administration–approved OraQuick HCV Rapid 
Antibody Test (OraSure Technologies Inc.) and the 
INNO-LIA HCV Score Assay (Fujirebio Europe 
N.V.). Participants with concordant HCV antibody–
negative results had no further follow-up. Participants 
with antibody-positive or indeterminate results from 
either assay underwent quantitative HCV RNA viral 
load testing, using the COBAS AmpliPrep/COBAS 
TaqMan HCV version 2.0 (Roche Diagnostics 
GmbH) at baseline and 6 months later. Statistical 
analyses were performed using Stata version 12 
(StataCorp).
DRC/CaNaDa
Two patients were identified, both of whom were 
born in DRC. The first patient (Kin619) was a 
70-year-old man belonging to the Baluba/Muluba 
ethnic group, sampled in a survey of elderly patients 
in Kinshasa(19) but originating from the Kasai region 
of DRC. The second sample (QC838) came from a 
male patient originally from DRC living in Canada. 
Serology was carried out using an INNO-LIA assay, 
and the presence of viral RNA was confirmed by 
RT-PCR.
BIologICal SaMpleS FoR 
SeQUeNCINg
A total of 13 × 2 HCV RNA–positive paired 
 samples taken 6 months apart and 11 HCV RNA–
negative control samples from the Ugandan study, 
together with two samples obtained from patients 
from the DRC, were available for analysis.
MetageNoMIC NeXt-
geNeRatIoN SeQUeNCINg
This was carried out using a metagenomic sequenc-
ing protocol as described.(20) Briefly, RNA was extrac-
ted from 200 µL of plasma using the Agencourt 
RNAdvance Blood Kit (Beckman Coulter) and reverse 
transcribed using SuperScript III (Invitrogen) with 
random hexamers and an NEB Second Strand Synth-
esis Kit (New England Biolabs). Next-genera tion 
sequencing (NGS) using adaptor-ligation library 
preparation (KAPA BioSciences) was carried out 
with several modifications. Complementary DNA 
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was purified with 0.9× AMPureXP magnetic beads 
(Beckman Coulter) using a “with-bead” approach. The 
concentration of DNA was measured with a Qubit 
2.0 fluorometer. Adapter-ligated DNA was amplified 
in real time on an ABI 7500 cycler, using a KAPA 
Hifi Real-Time Library Amplification Kit. Index tags 
FIg. 1. Uganda cohort characteristics. *HCV RNA quantification was carried out using the COBAS®AmpliPrep/COBAS®TaqMan® 
HCV Qualitative test v 2.0. OraQuick® and INNO-LIATM tests were conducted simultaneously.
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were added using NEBnext multiplex oligonucle-
otides (New England BioLabs). Amplified DNA was 
purified using AMPure XP beads and eluted in a final 
volume of 15 uL. An Agilent 2200 TapeStation was 
used to verify the final size profile of amplified library 
DNA. Up to 12 DNA libraries with appropriate index 
tags were pooled, and 2 × 150–nucleotide paired-end 
sequence data sets were generated on an Illumina 
MiSeq instrument using 300-cycle v2 reagents.
SaNgeR SeQUeNCINg
Viral RNA was extracted from 263 µL of serum 
using the QIAamp Virus BioRobot MDx Kit (Qiagen). 
Reverse transcription and single-round DNA amplifi-
cation by PCR were performed as described.(21) PCR 
products were purified and sequenced bidirectionally 
on an ABI Prism 3100xl genetic analyzer (Applied 
Biosystems).
BIoINFoRMatIC aNalySIS
De novo assembly (dipSPAdes) and mapping were 
carried out using Tanoti (http://www.bioinformatics.
cvr.ac.uk/tanoti.php). Sequence data were submitted to 
GenBank (accession numbers to follow). Polymorphisms 
were identified for currently reported resistance muta-
tions and selected epitopes using coordinates based on 
the H77 g1a reference strain (AF009606).
Alignments were carried out using MAFFT and 
manually adjusted as required. Uncorrected pairwise 
distance (p-distance) was calculated using MEGA 7.0. 
Sliding window p-distance was calculated with a sliding 
window of 30 base pairs using SSE software. Maximum 
likelihood phylogenetic analysis was carried out using 
RaxML (GTR+G+I substitution model). To verify that 
an HCV strain represented a newly identified genotype, 
uncorrected genetic p-distances were calculated between 
these and the ORF of HCV sequences from all reported 
strains for which a near-full genome was available.
Recombination analysis was carried out using the 
following:
 (i)   Bootscanning, which records the statistical 
support for the grouping of a query sequence 
within a clade of reference sequences repre-
senting each genotype.
 (ii)   Genetic Algorithm for Recombination Detec- 
tion (datamonkey.org) using all HCV refer-
ence strains.
Patristic distances were calculated using Garli and 
RAxML. These distances were combined with pub-
lished estimates of HCV genome evolutionary rates 
to estimate sequence divergence time. Phylogenetic 
bootstrap support was calculated using 500-1,000 
bootstrap replicates. HCV reference sequences were 
obtained from the National Center for Biotechnology 
Information (NCBI) through the International 
Committee on Taxonomy of Viruses Web site 
(https://talk.ictvonline.org/ictv_wikis/f laviviridae/w/
sg_flavi/56/hcv-classification) and from the HCV-
GLUE resource (http://hcv.glue.cvr.ac.uk/).
Results
HCV SeRopReValeNCe 
eStIMateS
In the Uganda cohort, an HCV seroprevalence 
of 3.4% was estimated using the Elecsys Anti-HCV 
II ImmunoAssay (266 HCV participants who were 
seropositive and 7,484 participants who were sero-
negative) (Fig. 1). Given the variable performance of 
HCV antibody screening observed in the Ugandan 
population(22) and to clarify the accuracy of screen-
ing assays in current use, we carried out a nested 
case-control study of 565 participants consisting of 
197 cases (74% of screen-positives) and 368 controls 
(55% of a random sample of 667 individuals who were 
seronegative), to undergo additional testing using 
the OraQuick HCV Rapid Antibody Test and the 
INNO-LIA HCV Score Assay.
HCV seropositivity differed substantially by the 
assay used (Supporting Table S1), indicating a varia-
tion in performance among tests that was consistent 
with other reports. Among 565 Ugandan participants, 
the OraQuick tested positive in 18 individuals (3.2%), 
whereas the INNO-LIA assay tested 36 samples 
(6.4%) as seropositive. Sixteen individuals had con-
cordant positive serological results.
QUaNtItatIVe HCV RNa VIRal 
loaD teStINg
Ninety-nine (17.5%) of 565 participants had posi-
tive or indeterminate results based on OraQuick and 
INNO-LIA. Of these, 95 were tested for viral RNA; 
20 had detectable viral RNA at baseline (Fig. 2). Six 
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months later, 13/20 (65%) still had detectable RNA 
indicating chronic infection, whereas 7/20 (35%) had 
cleared viremia spontaneously.
Using RNA positivity detected by COBAS 
AmpliPrep/COBAS TaqMan, we compared the util-
ity of the OraQuick and INNO-LIA for identifica-
tion of active disease. We found the sensitivity of the 
OraQuick (65%) was lower than that of the INNO-
LIA (100%). Test “false positives” were more common 
in the INNO-LIA assay: Of 75 individuals who were 
RNA negative, 16 tested positive with INNO-LIA 
(specificity 78.7%) compared with 3/75 by OraQuick 
(specificity 96%). This result may reflect the natural 
history of spontaneous clearance (or previous treat-
ment) in some individuals or true false-positive results.
HCV SeQUeNCINg
Genomes containing the full ORF of HCV were 
obtained for 14/15 participants, and one partial genome 
sequence was obtained for one patient (QC838). Of 
these, 12 were identified as g4 and three clustered 
within g7. Participant characteristics are shown in 
Table 1. The depth and coverage of each genome 
obtained using NGS are shown in Supporting 
Table S2.
Within g4, four samples were identified as g4k, 
three were identified as g4v, four were identified as 
g4q, and one was identified as g4s. Table 2A shows 
the closest reference genotype of each sample and the 
p-distance of each full ORF sequence to the near-
est reference genome. Two highly divergent g7 full 
ORFs were also sequenced (one from the DRC, iso-
late Kin619-KP347322, and one from Uganda, iso-
late U288-KU861171). The p-distances of the ORF 
between these two strains and the nearest reference 
genome (7a_EF108306) were 30.3% and 20.5%, 
respectively. These two strains are likely to repre-
sent two newly identified subtypes of g7, although 
confirmation of a new HCV subtype requires the 
FIg. 2. Geographic origin and demographics of HCV infected individuals shown by genotye.
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identification of at least two strains for each sub-
type, according to current classification guidelines(6) 
(Table 2B). No evidence of recombination was 
detected in any sequence.
Two full g7 ORF sequences were generated using 
de novo assembly from the same Ugandan participant 
(U288) sampled 6 months apart. Variation across the 
genome (compared with the H77 reference strain) 
is shown in Supporting Fig. S1, and divergence over 
time is shown in Supporting Fig. S2. Over a 6-month 
period, four nucleotide substitutions were observed, 
one of which resulted in an amino acid change within 
NS4B.
Baseline consensus sequences from the whole g7 
ORFs were submitted to GenBank with accession 
numbers 7*_KU861171 (U288) and 7*_KP347322 
(Kin619). The assembled genome sequence of U288 
consisted of 9,571 nucleotides, corresponding to 
nucleotide positions 12 through 9,582 of the H77 ref-
erence sequence. The 5′ UTR consisted of 330 nucle-
otides, and the 3′ UTR consisted of 210 nucleotides. 
An ORF 3,016 amino acids long was present, and 
the amino acid lengths of the predicted cleavage pro-
teins were 191 (Core), 192 (E1), 368 (E2), 63 (P7), 
217 (NS2), 631 (NS3), 54 (NS4A), 261 (NS4B), 448 
(NS5A), and 591 (NS5B). The alternative reading 
frame gene (F gene), encoding the putative 125 amino 
acid F protein was also detected (Supporting Fig. S3). 
The predicted E2 and NS5A proteins of the 7*(U288) 
sequence contain 1 and 2 additional amino acid dif-
ferences in length, respectively, when compared with 
g7a. Genome regions of high variability are evident 
within the HCV genes E1 and E2, NS4A, NS4B, 
NS5A, and NS5B. The predicted secondary structure 
of the 5′ UTR is similar to that of other genotypes 
of HCV.
taBle 1. Uganda Cohort Characteristics: patient ethnicity, 
Sex, and age
Sample ID Survey Sex Age Ethnic Group
U49 Misenyi Male 90 Munyarwanda
U100 Kyamulibwa Male 48 Muganda
U149 Bulwadda Male 53 Muganda
U150 Bulwadda Male 65 Muganda
U275 Nakaseeta Male 48 Munyarwanda
U278 Nalunnya Female 50 Munyarwanda
U282 Nalunnya Male 61 Munyarwanda
U288 Nalunnya Female 77 Murundi
U294 Busoga Female 67 Muganda
U295 Busoga Male 60 Munyarwanda
U316 Butiti Male 67 Munyarwanda
U317 Butiti Male 69 Munyarwanda
U320 Butiti Male 60 Mufumbira
Kin619 DRC Male 70 Muluba
QC838 DRC Male — —
Abbreviation: ID, identifier.
taBle 2a. genotype and pairwise Distance of Full Coding Region HCV Sequences Compared With the  
Closest Reference Sequence
Patient
0 Months 6 Months
Closest Reference p-Distance* Closest Reference p-Distance
U49 4q_FJ462434 0.125
U100 4k_FJ462438 0.105 4k_FJ462438 0.103
U149 4q_FJ462434 0.107 4q_FJ462434 0.105
U150 4q_FJ462434 0.120 4q_FJ462434 0.120
U275 4k_FJ462438 0.105 4k_FJ462438 0.109
U278 4v_JX227959 0.130 4v_JX227959 0.127
U282 4q_FJ462434 0.179 4q_FJ462434 0.179
U288 7a_EF108306 0.303 7b_KX092342 0.303
U294 4v_JX227959 0.078 4v_JX227959 0.077
U295 4s_JF735136 0.111 4s_JF735136 0.113
U316 4v_JX227959 0.126 4v_JX227959 0.125
U317 4k_EU392171 0.101 4k_EU392171 0.098
U320 4k_EU392171 0.102 4k_EU392171 0.092
Kin619 7a_EF108306 0.205
*Uncorrected p-distance.
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For the DRC g7 Kin619 isolate, an ORF of 3,016 
amino acids was observed, with amino acid lengths of 
the predicted cleavage proteins being 191 (Core), 192 
(E1), 367 (E2), 63 (P7), 217 (NS2), 631 (NS3), 54 
(NS4A), 261 (NS4B), 447 (NS5A), and 592 (NS5B). 
The putative F protein length was terminated by a 
stop codon after 11 amino acids.
Using previous low, medium, and high estimates 
of rate of evolution of g1 HCV (0.000865, 0.001345, 
and 0.001785 substitutions per site per year respec-
tively)(23) and an estimate of the patristic p-distances 
among the g7 whole-genome sequences, we estimate 
that the time of the most recent common ancestor of 
g7 existed approximately 324 (242-501) years ago, in 
the late seventeenth century (calculated by dividing 
the p-distance divided by 2 by a previously estimated 
rate assigned to g1 HCV).
HCV pHylogeNetIC aNalySIS
Maximum likelihood phylogenetic analysis using 
available whole and partial reference genomes for 
g1-g7 is shown in Fig. 3A-C and Supporting Fig. 
S4. Because few whole HCV genomes have been 
sequenced in SSA (20 available through the HCV-
GLUE resource: accessed on May 21, 2018), a max-
imum likelihood phylogenetic analysis using only 
NS5B region sequences was carried out using 65 
available g4 strains (Supporting Fig. S4). g4k samples 
obtained from Uganda were found to cluster closely 
with g4k strains originating from Rwanda, South 
Africa, Gabon, the United Kingdom, and Canada. g4q 
samples were clustered with samples from Burundi 
and Rwanda; g4v samples were clustered with 
 samples originating in Cyprus, Rwanda, and Burundi; 
and g4s samples were clustered with a sequence 
obtained from a Canadian patient originating from 
East Africa.
The NS5B region phylogenetic analysis also 
revealed the shared ancestry of the putative newly 
identified subtypes of g7. The DRC isolate Kin619 
clustered most closely with g7a (EF108306), identified 
in a migrant originating from a similar region within 
DRC and with short NS5B fragments sequenced 
from three other DRC nationals living in Canada, 
DRC, or Belgium (Fig. 3B).(16,24)
HCV ReSIStaNCe aNalySIS
Polymorphisms at sites associated with in vitro and 
in vivo resistance in all major genotypes including g7 
are shown in Table 3A, and these polymorphisms in 
the Ugandan g4 samples are shown in Table 3B.
In the g7 samples, polymorphisms associated with 
resistance to NS3 and NS5A inhibitors in other gen-
otypes were present in the majority of samples.(25) 
Of particular note, the Y93H mutation (associated 
with a lowered 50% effective concentration [EC50] 
to ombitasvir, daclatasvir, and velpatasvir) is present 
in the majority of g7 genomes.(26) The Y93H natural 
polymorphism is present in only 3% of all sequences 
submitted to NCBI and occurs at a low frequency in 
other genotypes (e.g., in HCV g1, it represents 3.16% 
of sequences submitted to NCBI, and in g3, it rep-
resents 4.09% of sequences submitted to NCBI). The 
D168Q mutation, strongly associated with resistance 
to first-generation and second-generation NS3 pro-
tease inhibitors in g3, was also present in all g7 sam-
ples.(27) Although reported as a potential resistance 
mutation in g1, it is rare in non-g3 sequences, occur-
ring in 0% of g1 (0/22,386), g2 (0/443), g4 (0/308), 
g5 (0/57), and g6 (0/584) sequences longer than 500 
base pairs submitted to GenBank.
In the 12 Ugandan g4 samples, 36L and 86P in 
the NS3 gene and H58P in NS5A were observed in 
all 12 samples sequenced. These are genotype-specific 
variants and are also present in the majority of g4 
sequences on GenBank. In addition, the NS5A 28L/P 
and 30R/S variants were present in 83% of sequences 
(10/12), but the NS5A28-32 MPRMP motif recently 
associated with resistance in g4r infection was not 
detected.(9)
taBle 2B. Mean Within and Between genotype pairwise 
Distances of Full HCV Coding Region Reference Sequences
Genotype
Within Genotype Between Genotype
p-Distance* p-Distance
1 0.138 0.252
2 0.141 0.261
3 0.157 0.265
4 0.129 0.258
5 0.125 0.265
6 0.174 0.261
7 0.196 —
All — 0.302
*Uncorrected p-distance.
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HCV epItope aNalySIS
HCV strains sequenced in this study were com-
pared with four well-characterized epitopes (https://
www.iedb.org/) present in the Adenovirus 6/Modified 
vaccinia Ankara (Ad6/MVA) g1b vaccine in current 
clinical trials.(28) The immunodominant human leu-
kocyte antigen (HLA)-A02-restricted NS3 1,073 
CVNGVCWTV epitope present in the vaccine strain 
was variable at sites 1, 2, and 6 in the g4 samples 
from Uganda and at sites 1, 2, 3, 6, 8, and 9 in the 
g7 samples (Table 4A-D). Escape variants have not 
been well described at this site, and further studies 
will be required to investigate whether cross-reactive 
responses are generated with the vaccine. Variation 
was also present in all sequenced strains when com-
pared with the HLA-A02–restricted NS31,406 epitope 
KLSGLGINAV, specifically, at sites 1, 3, 4, and 7 in g4 
strains and at sites 3, 4, 5, 7, and 8 in the g7 samples. 
Within the HLA-A01–restricted epitope NS31,436 
(ATDALMTGY), a Y to F change was present at 
position nine in the majority of g4 strains and in one g7 
strain; this mutation is known to be an escape variant. 
Finally, the immunodominant HLA-B27–restricted 
FIg. 3. Phylogenetic analysis of HCV sequences from Uganda and DRC. (A) Genotype 7 whole ORF sequences with genotypes 1-6 
(collapsed for ease of viewing). (B) Genotype 7 samples NS5B sequences. (C) Genotype 4 whole ORF sequences HCV genotype was 
inferred using available whole ORF or NS5B sequences using maximum likelihood, based on the General Time Reversible model 
with gamma distributed rate among sites with invariant sites (GTR +G+I) and 500 bootstrap replicates. The tree with the highest log 
likelihood is shown.  The H77 genotype 1a strain (AF009606) is included in panels B and C as an outgroup.
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epitope NS5B2,841 ARMILMTHF was also found to 
contain escape variants in all g4 samples and in g7a. 
In g7b, 7*(U288) and 7*(Kin619), 2 variants were 
found that have not previously been tested in immu-
nological studies.
HCV aNtIBoDy–poSItIVe aND 
pCR-NegatIVe SaMpleS
Eleven samples from Uganda from participants 
with positive HCV serology (Elecsys positive plus 
either INNO-LIA or OraQuick positive) but no 
evidence of HCV RNA by PCR were selected for 
metagenomic NGS as controls and to look for the 
potential  presence of highly divergent HCV strains 
not detectable by standard PCR or antigen-based 
techniques. No Hepacivirus genomes were detected 
in the samples by mapping or de novo assembly-based 
methods.
Discussion
Elimination of HCV will not be an easy task; at 
least 70 million people around the world are infected, 
only 20% are aware of their diagnosis, and the roll-out 
taBle 3a. polymorphisms associated With Resistance: predicted Resistance-associated Variants in HCV genotype 7
Gene Location 1a* 1b 2a 3a 4a 5a 6a 7a 7b 7*(U288) 7*(Kin619)
NS3 V36 — — L L L L — L L L L
NS3 Q41 — — — — — — — — — — —
NS3 F43 — — — — — — — — — — —
NS3 T54 — — — — — — — G S — A
NS3 V55 — — — — — L — P — — P
NS3 Q80 — — G — — K K D E E E
NS3 Q86 P — P P P P P P P P —
NS3 R109 — — — — — — — — — — —
NS3 R155 — — — — — — — — — — —
NS3 A156 — — — — — — — — — — —
NS3 D168 — — — Q — E — Q Q Q Q
NS3 V170 I — I I — — I — R/G — —
NS3 E176 — — D S — — — Q A — Q
NS5A L23 — — — — — — — — — — M
NS5A K24 — — T S — Q Q — — — —
NS5A M28 — — — — V L F L L — L
NS5A Q30 — — — A L — R S S S C
NS5A L31 — — M — M — — — — — —
NS5A P32 — — — — — — — — — — —
NS5A F37 — — — — L — — L L I L
NS5A S38 — — — — — — — — — — —
NS5A H54 — — T T — S — N T T N
NS5A K56 R — R R T — T — M — K
NS5A H58 — — P P P P T P P G P
NS5A E62 — — N T D T V L N S L
NS5A A92 — — C E — — — S — — S
NS5A Y93 — — — — — T T H H H —
NS5B L159 — — — — — — — — — — —
NS5B S282 — — — — T — — — — — —
NS5B C316 — — — — — — — — — — —
NS5B L320 — — — — — — — — — — —
NS5B V321 — — — — — — — — — — —
*Reference sequences–accession numbers: 1a: M67463, 1b: EF032892, 2a: AY746460, 3a: X76918, 4a: Y11604, 5a: NC_009826, 6a: 
AY859526, 7a: EF108306.
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of new treatments will require major political and 
financial intervention.(2,29) In SSA, approximately 11 
million people are infected, the majority with geno-
types that have received little or no attention in clinical 
treatment or vaccine trials, and it is likely that geno-
types remain undiscovered. At the time of writing, the 
majority of HCV sequences obtained from SSA rep-
resent short regions of the HCV core or NS5B genes, 
and coverage of whole genes that encode the targets 
of DAA therapy is extremely sparse.(12)
In our population-based study in Uganda, we con-
firmed 20 cases of active HCV infection from 565 
individuals tested with multiple serological assays. We 
noted a preponderance of older individuals infected 
with HCV (age 48-90 years). This has been observed 
in African studies(10,11) and may reflect a cohort of 
individuals highly exposed to HCV in the past. Our 
assessment of HCV seroprevalence demonstrated 
variable performance between assays, consistent with 
other estimates for the region. The INNO-LIA assay 
was highly sensitive, with low specificity in keeping 
with false-positive results and spontaneous clearance 
in some individuals. Despite high sensitivity and 
specificity in European and US populations, we found 
in this Ugandan population that the HCV-Elecsys 
ImmunoAssay lacked specificity and sensitivity, below 
those reported elsewhere,(30) in keeping with previous 
seroprevalence studies in Uganda (Supporting Table 
S3). This was particularly apparent in participants 
who had an initial positive or indeterminate PCR 
result but a negative result 6 months later, indicating 
spontaneous clearance (in which antibody responses 
are known to lack sensitivity). Molecular techniques 
have an important role in improving active infection 
detection rates in SSA to facilitate elimination, and 
there was no evidence in this study that these lacked 
taBle 3B. polymorphisms associated With Resistance: predicted Resistance-associated Variants in HCV genotype 4 
Samples From Uganda
Gene Location 4k 4k 4k 4k 4s 4q 4q 4q 4q 4v 4v 4v
NS3 V36 L L L L L L L L L L L L
NS3 Q41 — — — — — — — — — — — —
NS3 F43 — — — — — — — — — — — —
NS3 T54 — — — — — — — — — — — —
NS3 V55 — — — — — — — — — — — —
NS3 Q80 — — — — — — — — — — — —
NS3 Q86 P P P P P P P P P P P P
NS3 R109 — — — — — — — — — — — —
NS3 R155 — — — — — — — — — — — —
NS3 A156 — — — — — — — — — — — —
NS3 D168 — — — — — — E — — — — —
NS3 V170 — — — — — — — — — — — —
NS5A L23 — — — — — — — — — — — —
NS5A K24 — — — — — — — — — — — —
NS5A M28 L L L L — P L L — L L L
NS5A Q30 R R S R — R R R — R R R
NS5A L31 — — — — — — M M — M M M
NS5A P32 — — — — — — — — — — — —
NS5A F37 L L L L — L L L — L L L
NS5A S38 — — — — — — — — — — — —
NS5A H54 — — — — — — — — — — — —
NS5A K56 T T T — T T T T T T R T
NS5A H58 P P P P P P P P P P P P
NS5A E62 A — — — — — — — — — — —
NS5A A92 — — — — — — — — — — — —
NS5A Y93 — — — — — — — — — — — —
NS5B L159 — — — — — — — — — — — —
NS5B S282 — — — — — — — — — — — —
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sensitivity. Using whole-genome metagenomic NGS, 
we found that the most prevalent HCV genotypes in 
our sample population in Uganda were g4k, g4q, g4v, 
and g4s. We also sequenced three g7 samples, two of 
which represent putative newly identified HCV sub-
types. Despite a low level of sampling, g7 appears to 
be highly diverse, with at least three phylogenetic 
lineages. There is a need to understand more about 
the diversity of viruses in DRC, Uganda, and other 
countries in SSA because of the potential impact of 
viral genetic diversity on diagnostic assay sensitivity, 
treatment response rates, and vaccine design.
g4 HCV is estimated to have originated in Central 
Africa in the early eighteenth century.(31) In this 
study, we used metagenomic NGS to obtain the 
first full ORF HCV sequences from participants in 
Uganda. The most common genotype detected was 
g4k, strains of which have been detected in persons 
across Central Africa (DRC, Republic of the Congo, 
Central African Republic, Rwanda, Cameroon, and 
Gabon) and North Africa (Tunisia) and in infected 
migrants in Europe (United Kingdom, France, 
and Belgium) and North America (Canada). One 
Ugandan sequence clustered with the g4s reference 
sequence (obtained from an unspecified region of 
East Africa(32)). Three samples (each sequenced on 
two occasions 6 months apart) clustered within g4v 
alongside sequences obtained from Rwanda, Burundi, 
and Cyprus. Four samples clustered within subtype 
g4q alongside sequences from Rwanda and Burundi. 
In the participants sampled from Uganda, 7/13 were 
of Munyarwanda ethnicity; this ethnic group rep-
resents only 6% of the Ugandan population and was 
therefore overrepresented in the study. Interestingly, 
three of these isolates clustered with reference samples 
from Rwanda (two g4k samples, U275 and U317, and 
one g4q sample, U282). Given the participant ages, 
and the history of migration from Rwanda to Uganda 
in the 1960s and the 1990s, it is likely that some of 
these individuals were born and infected in Rwanda.
Despite the widespread distribution of these g4 
strains, they have not featured in published clinical 
trials to date (unlike subtypes g4a and g4d).(33-36) The 
impact of resistance-associated substitutions (RASs) 
on DAA susceptibility is known to vary by HCV 
subtype; for example, in g1 HCV, the NS5A Y93H 
variant causes high-level resistance in g1a (~600-fold 
increase in EC50) compared with g1b (<10-fold). 
Concerningly, patients with cirrhosis originating from 
Somalia with the g4r variant were recently found 
taBle 4a. epitope Variation Within genotype 4 and 7 Strains: NS31,073
Sample NS31,073 Peptide Motif (HLA-A02–Restricted)
Vaccine (g1b)* C V N G V C W T V
Escape variant None described
Genotype 4 samples
U100 (4k) G I — — — M — — —
U275 (4k) G I — — — M — — —
U317 (4k) G I — — — M — — —
U320 (4k) G I — — — M — — —
U149 (4q) A — — — — M — — —
U150 (4q) A — — — — M — — —
U282 (4q) A — — — — M — — —
U49 (4q) A — — — — M — — —
U295 (4s) A I — — — M — — —
U278 (4v) A — — — — M — — —
U294 (4v) A — — — — M — — —
U316 (4v) A — — — — M — — —
Genotype 7 samples
EF108306.2 G7a N — G — — M — G —
KX092342.1 G7b S I S — — — — S —
KU861171.1 G7*(U288) V C — — — — — — —
KP347322 G7*(Kin619) V L S — — — — A P
*Ad6 vaccine based on M58335.1 strain.
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to have a reduced response to DAA treatment in 
the National Health Service England Early Access 
Programme in association with the MPRMP NS5A28-
32 amino acid motif that is associated with high-level 
resistance in vitro.(9,37) In another meta-analysis of 
patients with genotype 4 infection treated with ledip-
asvir and sofosbuvir, treatment failure occurred in two 
thirds of patients with subtype g4r and in one patient 
with g4b. These participants had baseline RASs 
(28M/V+30R+31M), which remained the dominant 
sequences posttreatment.(38) The MPRMP motif was 
not present in the Ugandan samples, but multiple poly-
morphisms associated with NS5A resistance in other 
genotypes were present in all samples and included 
28L, 31M, 30R, and 58P. Further clinical trials are 
required to investigate response to DAA treatment in 
patients infected with these genotypes, particularly in 
patients at highest risk of lack of response to ther-
apy, such as those with liver cirrhosis. Encouragingly, 
treatment with newer combination DAA regimens 
including velpatasvir appears to be highly effective for 
g4r (sofosbuvir, velpatasvir ± voxilaprevir).(39)
The first full g7 HCV genome (g7a) was first iden-
tified in a Canadian migrant from DRC in 2007.(16) 
Another highly divergent g7 strain (g7b) was recently 
identified in a patient also originally from DRC.(24) 
Partial genome sequences from four other DRC 
nationals residing in Belgium, France, and Canada 
have also been reported. Our study reveals another 
two highly divergent near-full g7 genomes (U288 
and Kin619) and one newly identified partial genome 
(QC838), in participants originating from the DRC 
and Uganda, increasing the recorded diversity and 
geographical range of this genotype. The identifica-
tion of a new HCV subtype requires that the nucle-
otide sequence differs within the coding region by 
at least 15%, and different genotypes typically differ 
from each other by 30% at the nucleotide level.(6) 
taBle 4B. epitope Variation Within genotype 4 and 7 Strains: NS31,406
Sample NS31,406 Peptide Motif (HLA-A02–Restricted)
Vaccine (g1b) K L S G L G I N A V
Escape variant (g1)* — — V A — — — — — —
Escape variant (g1) — — V A — — V — — —
Escape variant (g3) — — R — M — L — — —
Escape variant (g3) R — R — M — L — — —
Cross-reactive strain† — — — — — — L — — —
Cross-reactive strain — — — S — — L — — —
Genotype 4 samples
U100 (4k) Q — — S — — L — — —
U275 (4k) Q — — S — — L — — —
U317 (4k) Q — — S — — L — — —
U320 (4k) Q — — S — — L — — —
U149 (4q) H — — A — — L — — —
U150 (4q) Q — — A — — — — — —
U282 (4q) Q — — A — — V — — —
U49 (4q) Q — — S — — L — — —
U295 (4s) Q — — S — — L — — —
U278 (4v) Q — — G — — L — — —
U294 (4v) Q — L G — — — — — —
U316 (4v) Q — — G — — L — — —
Genotype 7 samples
EF108306.2 G7a — — T S — — L T — —
KX092342.1 G7b — — R N A — L — — —
KU861171.1 G7*(U288) — — R T M — — — — —
KP347322 G7*(Kin619) — — T S — — V T — —
*Variants described in www.iedb.org.
†Cross-reactive strains but associated with reduced affinity using peptide dilution assays.
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Maximum likelihood analysis of g7 shows that a dis-
tinct monophyletic lineage with strong bootstrap sup-
port and variation is present across the genome. The 
U288 sample from Uganda almost meets the criteria 
for a newly identified genotype (sitting at the upper 
end of variation found within genotypes but at the 
lower end for intergenotypic variation). This is com-
parable with the distance found between more diver-
gent strains of g3 or g6. It has been assigned here to 
g7 based on phylogeny (genetic distance alone has 
been shown to be an inadequate measure for assign-
ing new genotypes). No evidence of recombination 
was detected in these genomes; HCV recombinant 
genomes are rare but have been reported, including 
two recently detected g1/4 variants in patients from 
Cameroon.(40) The 5′ UTR of the genome is highly 
structured and relatively conserved compared with 
other genotypes. The amino acid lengths of the pre-
dicted cleavage proteins are similar to those found in 
the most closely related g7a subtype, with additional 
insertions in E2 and NS5A. Highest p-distances were 
seen in the envelope genes, NS4A, NS4B, and NS5A. 
An ORF covering 375 nucleotides (125 amino acids) 
of the putative F protein gene was also present in U288 
but not in Kin619. Based on this expanded analysis of 
g7 sequences, the origin of g7 HCV appears to be in 
East or Central Africa. Using previous calculations of 
rate of evolution of HCV, the common ancestor of g7 
is likely to have been in the late seventeenth century.
A major concern is the sensitivity of g7 and other 
genotypes, especially g4 variants prevalent in SSA, to 
treatment with DAAs and whether reduced sensitiv-
ity will affect elimination plans set out by WHO. g7 
sequences harbor D168Q and Y93H mutations; these 
are associated with high-level resistance to most NS3 
protease inhibitors and NS5A inhibitors, respectively. 
Other variants are present within NS5A and NS3 
that require further characterization through in vitro 
replicon and clinical studies. No guidance exists to 
date for the treatment of g7 infection. Recombinant 
Japanese fulminant hepatitis 1 ( JFH1)/J6 (g2a/1b) 
strains expressing g7a NS4A/NS5A have been devel-
oped but are associated with poor replication; further 
development of these may aid testing of DAAs in the 
future.(26,41) One patient to date has been successfully 
treated with a combination of sofosbuvir and velpa-
tasvir for g7 infection (mistyped in the ASTRAL-1 
study as g2).(42) The newer pangenotypic combination 
therapies sofosbuvir, voxilaprevir, and velpatasvir and 
taBle 4C. epitope Variation Within genotype 4 and 7 
Strains: NS31,436
NS31,436 Peptide Motif (HLA-A01–Restricted)
Vaccine (g1b) A T D A L M T G Y
Escape variant — — — — — — — — F
Genotype 4 samples
U100 (4k) — — — — — — — — F
U275 (4k) S — — — — — — — F
U317 (4k) — — — — — — — — F
U320 (4k) — — — — — — — — F
U149 (4q) — — — — — — — — —
U150 (4q) — — — — — — — — —
U282 (4q) — — — — — — — — F
U49 (4q) — — — — — — — — F
U295 (4s) — — — — — — — — F
U278 (4v) — — — — — — — — —
U294 (4v) — — — — — — — — F
U316 (4v) — — — — — — — — F
Genotype 7 samples
EF108306.2 G7a — — — — — — — — F
KX092342.1 G7b — — — — — — — — —
KU861171.1 G7*(U288) — — — — — — — — —
KP347322 G7*(Kin619) — — — — — — — — —
taBle 4D. epitope Variation Within genotype 4 and 7 
Strains: NS5B2,841
NS5B2,841 Peptide Motif (HLA-B27–Restricted)
Vaccine (g1b) A R M I L M T H F
Escape strain (g3) V — — V M — — — —
Escape strain (g1) V — — V — L — — —
Escape strain (g1) V — — V — — — — —
Escape strain (g1) V — — V — S — — —
Escape strain (g1) V — — — — L — — —
Genotype 4 samples
U100 (4k) V — — V — — — — —
U275 (4k) V — — V — — — — —
U317 (4k) V — — V — — — — —
U320 (4k) V — — V — — — — —
U149 (4q) V — — V — — — — —
U150 (4q) V — — V — — — — —
U282 (4q) V — — V — — — — —
U49 (4q) V — — V — — — — —
U295 (4s) V — — V — — — — —
U278 (4v) V — — V — — — — —
U294 (4v) V — — V — — — — —
U316 (4v) V — — V — — — — —
Genotype 7 samples
EF108306.2 G7a V — — V — — — — —
KX092342.1 G7b V — T V F — — — —
KU861171.1 G7*U288) V — — V F — — — —
KP347322 G7*(Kin619) V — — V F — — — —
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glecaprevir and pibrentasvir are less likely to fail in 
the presence of mutations such as Y93H in other gen-
otypes, so these may prove to be effective; however, 
no studies in g7 have yet been carried out. g7 HCV 
has been shown to be mistyped as g2 in other studies 
using the TRUGENE assay; this could result in errors 
in therapeutic decision making, and the adoption of 
full genome sequencing using more sophisticated 
technologies such as metagenomic and target enrich-
ment–based NGS may reveal other “rare” genotypes 
as a cause of treatment failure as treatment is rolled 
out.(9,20,24) Unbiased metagenomic NGS sequenc-
ing overcomes the need for specific primers for full 
genome sequencing and may therefore help to iden-
tify new strains that would not have been amplified 
using PCR-based methodology. It does not appear, 
however, that diagnosis of HCV is impaired with 
standard assays.
The presence of divergent HCV strains is also of 
central importance in the efforts to design an effec-
tive HCV vaccine. A vaccine candidate designed to 
target the cytotoxic T lymphocyte response based on 
an adenoviral prime and MVA boost backbone with 
the addition of g1b nonstructural genes is in cur-
rent clinical trials in the United States.(4,28) When 
we examined four well-characterized epitopes likely 
to be targeted following vaccination with the Ad6 
g1b vaccine, described escape mutations were pres-
ent in the HLA-B27–restricted NS5B2,841 epitope 
and the HLA-A01–restricted NS31,436 epitope in 
the g4 and the g7 strains, whereas variants that have 
not previously been investigated were present at the 
HLA-A02–restricted NS31,073 and NS31,406 epitope 
sites. Further work will be required to assess cross- 
reactivity using these peptides in vaccinated individ-
uals. It is possible that future iterations of the vaccine 
will require modification at these and other sites for 
use in SSA.
In conclusion, the prevalence and genetic diversity 
of HCV in East and Central Africa is only partially 
characterized and requires further investigation to 
evaluate diagnostic assay sensitivity, disease burden, 
and response to treatment and to enhance vaccine 
design.
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